StockData
Elevance Health, Inc. logo

Elevance Health, Inc. (ELV) operating KPIs

ELVNYSEHospital & Medical Service PlansFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Oct 21, 2026Score 15/3012% below fair value
$420.07−1.95 (-0.46%)

Close on Oct 30, 2026Market cap $91.10BP/E 18.7Yield –

Elevance Health aFS Securities in Continuous Unrealized Loss Position (< 12 Months) — Fair Value ($M)

Quarterly figures from Elevance Health's filings and investor materials

QuarterlyAnnual
Latest, Q3 2026
20,508
Period ended Sep 30, 2026
Change on a year earlier
+619.3%
2,851 in Q3 2025
History
13 quarters
Since Q4 2022
Sources
2
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAFS Securities in Continuous Unrealized Loss Position (< 12 Months) — Fair Value ($M)Year on yearSource
Q3 2026Sep 30, 202620,508+619.3%ELV 10-Q (XBRL us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss) ↗
Q2 2026Jun 30, 20269,338+109.0%ELV 10-Q (XBRL us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss) ↗
Q1 2026Mar 31, 20269,041+44.8%ELV 10-Q (XBRL us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss) ↗
Q4 2025Dec 31, 20253,594-61.0%ELV 10-Q (XBRL us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss) ↗
Q3 2025Sep 30, 20252,851+246.8%ELV 10-Q (XBRL us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss) ↗
Q2 2025Jun 30, 20254,467-43.9%ELV 10-Q (XBRL us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss) ↗
Q1 2025Mar 31, 20256,242+6.6%ELV 10-Q (XBRL us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss) ↗
Q4 2024Dec 31, 20249,213+241.3%ELV 10-K (XBRL us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss) ↗
Q3 2024Sep 30, 2024822–ELV 10-Q (XBRL us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss) ↗
Q2 2024Jun 30, 20247,964–ELV 10-Q (XBRL us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss) ↗
Q1 2024Mar 31, 20245,855–ELV 10-Q (XBRL us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss) ↗
Q4 2023Dec 31, 20232,699-83.2%ELV 10-K (XBRL us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss) ↗
Q4 2022Dec 31, 202216,035–ELV 10-K (XBRL us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss) ↗

Breakdown

What makes up afs securities in continuous unrealized loss position (< 12 months) — fair value

Cite this data

StockData. (2026). Elevance Health AFS Securities in Continuous Unrealized Loss Position (< 12 Months) — Fair Value ($M), quarterly Q4 2022–Q3 2026 [Data set]. Compiled from Elevance Health SEC filings and investor materials. https://stockdatahq.com/stocks/elv/kpis/inv_loss_pos_lt12m_fv

See every metric in the Elevance Health KPI table. Data updated Oct 28, 2026.